Decision Aid Summary
|Title||Adjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer|
|Audience||Women who are post-menopausal with hormone receptor-positive (ER+ and/or PR+) breast cancer considering adjuvant endocrine therapy after having surgery, radiation, and/or chemotherapy.|
|Options included||Take tamoxifen.
Take an aromatase inhibitor.
Take tamoxifen first, then switch to an aromatase inhibitor.
|Year of last update or review||2018|
|How to obtain||Click here to view the decision aid on the developer website|
|Developer||American Society of Clinical Oncology (ASCO)|
|Where was it developed?||www.asco.org/guidelines, email@example.com
American Society of Clinical Oncology
|Health condition||Breast Cancer|
|Type of decision aid||Treatment|
|Based on IPDAS criteria (International Patient Decision Aid Standards) this decision aid (and/or supporting materials) meets:|
|6 out of 7 criteria to be defined as a patient decision aid|
|6 out of 9 criteria to lower the risk of making a biased decision|
|Not applicable: other criteria for decision aids about screening or testing|
Last modified: 2019-06-26.